All Stories

  1. PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay

    Article • Current Drug Targets, December 2020, Bentham Science Publishers

    Dr Matteo Santoni, Liang Cheng

  2. Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma

    Article • Current Drug Targets, March 2020, Bentham Science Publishers

    Dr Matteo Santoni

  3. An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer

    Article • Expert Review of Molecular Diagnostics, October 2019, Taylor & Francis

    Dr Matteo Santoni, Liang Cheng

  4. Liquid biopsy in the clinical management of bladder cancer: current status and future developments

    Article • Expert Review of Molecular Diagnostics, October 2019, Taylor & Francis

    Dr Matteo Santoni, Liang Cheng

  5. Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies

    Article • Expert Review of Molecular Diagnostics, September 2019, Taylor & Francis

    Dr Matteo Santoni, Liang Cheng

  6. Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy

    Article • Current Drug Metabolism, June 2019, Bentham Science Publishers

    Dr Matteo Santoni

  7. Quick steps toward precision medicine in renal cell carcinoma

    Article • Expert Review of Precision Medicine and Drug Development, August 2018, Taylor & Francis

    Dr Matteo Santoni

  8. Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer

    Article • Expert Review of Molecular Diagnostics, June 2018, Taylor & Francis

    Dr Matteo Santoni

  9. Tivozanib for the treatment of renal cell carcinoma

    Article • Expert Opinion on Pharmacotherapy, May 2018, Taylor & Francis

    Dr Matteo Santoni

  10. Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma

    Article • Expert Review of Anticancer Therapy, April 2018, Taylor & Francis

    Dr Matteo Santoni

  11. Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis

    Article • Future Oncology, December 2015, Future Medicine

    Dr Matteo Santoni, Dr Camilo Porta

  12. Role of STAT3 pathway in genitourinary tumors

    Article • Future Science OA, November 2015, Future Science

    Dr Matteo Santoni, Liang Cheng

  13. Correction: Liberati, S., et al. Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor Progression. Cells 2014, 3, 112–128

    Article • Cells, June 2014, MDPI AG

    Dr Matteo Santoni

  14. Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients

    Article • Cellular and Molecular Immunology, June 2014, Springer Science + Business Media

    Dr Matteo Santoni

  15. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy

    Article • British Journal of Clinical Pharmacology, May 2014, Wiley

    Dr Matteo Santoni

  16. Thymic neoplasms: An update on the use of chemotherapy and new targeted therapies. A literature review

    Article • Cancer Treatment Reviews, May 2014, Elsevier

    Dr Matteo Santoni

  17. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma

    Article • Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, April 2014, Elsevier

    Dr Matteo Santoni

  18. Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.

    Article • Canadian Urological Association Journal, March 2014, Canadian Urological Association Journal

    Dr Matteo Santoni

  19. Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials

    Article • Cancer Treatment Reviews, March 2014, Elsevier

    Dr Matteo Santoni

  20. Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor Progression

    Article • Cells, February 2014, MDPI AG

    Dr Matteo Santoni

  21. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials

    Article • International Journal of Cancer, February 2014, Wiley

    Dr Matteo Santoni

  22. [11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas

    Article • ISRN Oncology, February 2014, Hindawi Publishing Corporation

    Dr Matteo Santoni

  23. CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors

    Article • BioMed Research International, January 2014, Hindawi Publishing Corporation

    Dr Matteo Santoni

  24. Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy

    Article • Gastroenterology Research and Practice, January 2014, Hindawi Publishing Corporation

    Dr Matteo Santoni

  25. Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey

    Article • PLoS ONE, December 2013, PLOS

    Dr Matteo Santoni

  26. Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside

    Article • Cancer and Metastasis Reviews, December 2013, Springer Science + Business Media

    Dr Matteo Santoni

  27. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type‐2

    Article • International Journal of Cancer, December 2013, Wiley

    Dr Matteo Santoni

  28. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR‐TKIs and mTOR inhibitor

    Article • International Journal of Cancer, November 2013, Wiley

    Dr Matteo Santoni

  29. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta‐analysis of clinical trials

    Article • International Journal of Cancer, November 2013, Wiley

    Dr Matteo Santoni

  30. Epigenetic, Genetic, and Acquired Regulation of Cav3 T-Type Calcium Channel Expression and Function in Tumor Growth and Progression

    Article • November 2013, Springer Science + Business Media

    Dr Matteo Santoni

  31. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma

    Article • Cancer Immunology Immunotherapy, October 2013, Springer Science + Business Media

    Dr Matteo Santoni

  32. Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives

    Article • Expert Review of Anticancer Therapy, June 2013, Taylor & Francis

    Dr Matteo Santoni, Dr Michele Milella, MICHELE DE TURSI, Giovanni Lo Re

  33. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort

    Article • European Journal of Cancer, June 2013, Elsevier

    Dr Matteo Santoni

  34. Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma

    Article • Journal of Neuro-Oncology, April 2013, Springer Science + Business Media

    Dr Matteo Santoni

  35. Essential Role of Gli Proteins in Glioblastoma Multiforme

    Article • Current Protein and Peptide Science, April 2013, Bentham Science Publishers

    Dr Matteo Santoni

  36. TRP Channels: New Potential Therapeutic Approaches in CNS Neuropathies

    Article • CNS & Neurological Disorders - Drug Targets, April 2013, Bentham Science Publishers

    Dr Matteo Santoni

  37. Role of maspin in cancer

    Article • Clinical and Translational Medicine, March 2013, Wiley

    Dr Matteo Santoni

  38. Oncogenic and Anti-Oncogenic Effects of Transient Receptor Potential Channels

    Article • Current Topics in Medicinal Chemistry, March 2013, Bentham Science Publishers

    Dr Matteo Santoni

  39. Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?

    Article • Current Cancer Drug Targets, March 2013, Bentham Science Publishers

    Dr Matteo Santoni

  40. The role of transient receptor potential vanilloid type-2 ion channels in innate and adaptive immune responses

    Article • Frontiers in Immunology, January 2013, Frontiers

    Dr Matteo Santoni

  41. Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma

    Article • BioMed Research International, January 2013, Hindawi Publishing Corporation

    Dr Matteo Santoni

  42. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents

    Article • Carcinogenesis, October 2012, Oxford University Press (OUP)

    Dr Matteo Santoni

  43. Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study

    Article • Oncology Letters, July 2012, Spandidos Publications

    Dr Matteo Santoni

  44. Present and Future of Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: Analysis of Hematologic Toxicity

    Article • Recent Patents on Anti-Infective Drug Discovery, June 2012, Bentham Science Publishers

    Dr Matteo Santoni

  45. Functional role of T‐type calcium channels in tumour growth and progression: prospective in cancer therapy

    Article • British Journal of Pharmacology, May 2012, Wiley

    Dr Matteo Santoni

  46. A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy

    Article • Journal of Translational Medicine, May 2012, Springer Science + Business Media

    Dr Matteo Santoni

  47. Tumor Angiogenesis: A Target for Renal Cell Carcinoma Therapy. Current Perspectives and Novel Strategies

    Article • Recent Patents on Biomarkerse, May 2012, Bentham Science Publishers

    Dr Matteo Santoni

  48. The transient receptor potential vanilloid‐2 cation channel impairs glioblastoma stem‐like cell proliferation and promotes differentiation

    Article • International Journal of Cancer, April 2012, Wiley

    Dr Matteo Santoni

  49. Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder

    Article • Advances in Urology, January 2012, Hindawi Publishing Corporation

    Dr Matteo Santoni

  50. New Insight on the Role of Transient Receptor Potential (TRP) Channels in Driven Gliomagenesis Pathways

    Article • November 2011, IntechOpen

    Dr Matteo Santoni

  51. Capsaicin promotes a more aggressive gene expression phenotype and invasiveness in null-TRPV1 urothelial cancer cells

    Article • Carcinogenesis, February 2011, Oxford University Press (OUP)

    Dr Matteo Santoni

  52. New deals on the transcriptional and post-transcriptional regulation of TRP channel target genes during the angiogenesis of glioma

    Article • Journal of Experimental and Integrative Medicine, January 2011, ScopeMed International Medical Journal Management and Indexing System

    Dr Matteo Santoni